List of Biotech, Pharmaceutical & Life Sciences companies in Netherlands - 147

2-BBB is developing medicines for the treatment of devastating brain diseases. Our proprietary liposomal G-Technology® facilitates entry to the brain while simultaneously enabling sustained delivery of systemically administered therapeutics. Our technology has been shown to be compatible with approved as well as novel therapeutic entities. We have two clinical programs, one targeting multiple indications of brain cancers and the other neuro-inflammatory diseases.

Ace has been delivering custom pharmaceutical solutions for specific patient needs for over 30 years. With our own registrations, compounded products and cosmetics we provide a solution for pharmacists all over the world. In addition we make clinical trial medication on behalf of our customer.

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases.

Aiosyn is a Dutch healthtech company that is developing precision pathology software solutions for breast cancer and chronic kidney disease. Aiosyn launched its first automated QC test on the EU market (AiosynQC) and the first clinical diagnostic test for breast cancer is pending regulatory approval in the EU. With our NephroPath platform we support CROs and Biopharma with quantifying kidney biomarkers thereby accelerating (pre-)clinical drug development studies.

Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

Introduction NannoStar® and NutriSpring® are a premium quality micro-algae products for producers and end users in aquaculture and human nutrition. NannoStar and NutriSpring are 100% Dutch quality microalgae products and produced in a pristine location at the banks of the IJsselmeer at the edge of the largest protected natural area of the Netherlands. Our microalgae are grown on ancient borehole seawater (Pleistocene 130.000 years old) which is free of contamination and heavy metals. The water is extracted from 80 meters below the surface. NannoStar® and NutriSpring® are year round produced in a full controlled photobioreactor system by our dedicated team of PhD microbiologists who have 20 years of combined experience in microalgae production. The microalgae are grown on selected food grade nutrients under ISO22000 and GMP+ certification. Natural and sustainable The AlgaSpring team developed an advanced algae production system which enables the production of premium quality marine microalgae at a competitive cost level. AlgaSpring micro algae are produced environmentally friendly and no pesticides or herbicides are used. We use selected, natural algal strains and pure water and nutrient sources. Production batches are continuously monitored for quality control. AlgaSpring microalgae are cultivated in a mono-specific culture under controlled conditions in a semi-continuous process with optimum provision of nutrients, CO2, light and mixing. Cultivation and processing conditions are standardized which ensures a constant quality and a high content of valuable components in the microalgae product. AlgaSpring microalgae are produced with just daylight and no additional heating other than to keep the production facility frost free during the winter. Our marine climate zone with cool summers and mild winters ensures us of year round production at the best quality.

Alveron Pharma is developing a unique coagulation platform technology with the world's first cyclodextrin-based anticoagulant reversal drug

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use. Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

AM-Pharma BV is a biopharmaceutical company developing recombinant Alkaline Phosphatase for clinical use.

AM–Pharma is a biopharmaceutical company developing proprietary recombinant human Alkaline Phosphatase (AP) therapeutics, which have the potential to transform the treatment prospects for patients with Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia.

Amphera is a late-stage biotechnology company developing cell therapies to treat cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.

AMT Medical is a clinical-stage medical device company based in Ede, Netherlands, with additional facilities in Utrecht. Founded in 2015, the company specializes in developing innovative solutions for cardiac and neurosurgical bypass procedures. Their focus is on transforming bypass surgery through minimally invasive techniques, which include off-pump heart bypass surgery that avoids stopping the heart or fully opening the chest. The company offers a Cardiac Bypass System designed for keyhole and robotic surgery, which has successfully completed First-in-Human trials and is currently undergoing CE certification in Europe. Additionally, AMT Medical has commercialized a Neurosurgical Bypass Device, recognized as a Class III medical device in the EU and U.S., and noted for its life-saving capabilities. With multiple patents protecting their technology, AMT Medical aims to set a new standard in the $15 billion coronary artery disease market, targeting cardiac and neurosurgeons with their advanced solutions.

Angiocare is the only visionary and vibrant medical device partner, that distributes high quality and innovative products through knowledge and passion of our people. To a broad range of healthcare professionals and hospital administrations, who want to work with a trustworthy, do as you say-company bringing added value to a rapid changing healthcare environment with a personal touch. Angiocare is recognized as the no. 1 independent distributor in The Netherlands focusing on diagnostic and interventional therapeutic solutions in the field of Cardiology, (Neuro) Radiology, Vascular Surgery and Interventional Oncology. AngioCare is focusing primarily on cardiovascular solutions and products. We have an international network of innovative suppliers and we often bring new technologies to the Benelux countries. Our experienced sales employees are recognized as "solution bringers" in the emerging field of the mentioned markets and our logistics and order management employees have over 10 years experience in this specialized market segment. Together with our suppliers we have conducted or are conducting registries or trials with new innovative technologies to show clinical benefits for our patients.

Bespoke promoters and enhancers, for any tissue, any organism. At Annogen, our vision is a future where safe and effective advanced therapies are specifically expressed in the right tissues with no off-target effects. We believe that this can be achieved by bespoke promoters (genetic switches) and genomic expression sites. Therefore, Annogen is on a mission towards becoming the leading expertise center for gene expression engineering in order to improve the safety and effectiveness of tomorrow's cell and gene therapies. Annogen leverages its proprietary SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein and virus production. In addition, we develop service projects based on our proprietary AIM™ technology to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches typically enable big improvements in any biomedical strategy involving the (over-) expression of genes. Annogen was founded in 2017 by Dr. Joris van Arensbergen, who developed and published the SuRE™ technology as a post-doctoral fellow in the laboratory of Prof. Dr. Bas van Steensel at the world-renowned Netherlands Cancer Institute (NKI). Today, Annogen is the trusted partner for bespoke gene expression engineering for leading biopharmaceutical, agricultural and academic research centers globally.

ANT Neuro is a Dutch corporation specialized in the development, marketing and sales of medical and research applications. ANT Neuro was established in 1997 as a spin-off company of The University of Twente, Enschede. It now has offices located in Hengelo, Netherlands; Berlin, Germany; London, UK; Philadelphia, USA; Melbourne, Australia; and Hong Kong, China. ANT Neuro specializes in being a single-source provider of high performance products within neuroscience research and neurodiagnostics. Applications include EEG, EMG, TMS and MEG technology.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years. More information can be found on www.atromedical.com

Audion Therapeutics is a private biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of acquired hearing loss. Audion’s headquarters are in Amsterdam, The Netherlands with a presence in the Boston area. Founders are Professor Albert Edge of the MEEI (Harvard Medical School) in Boston, Dr Helmuth van Es, founder of Galapagos, Citryll, Antabio and Effecta Pharma and Rolf Jan Rutten CEO. Investors are Eli Lilly and Inkef Capital and the early clinical development of its lead compound LY3056480 was also funded by a Horizon2020 grant from the EU for a consortium of ENT clinical sites in UK, Germany and Greece.

Avantium develops and commercialises innovative chemistry technologies in order to produce chemicals and materials based on renewable feedstock instead of fossil resources. Our two lead products are FDCA and plantMEG™. Together, they enable the production of the novel plastic PEF: 100% plant-based, recyclable and degradable with superior performance. Avantium also provides advanced catalysis products and services to organisations who desire to gain efficiency in their processes.

At Avidicure, we invent and develop entirely new antibody therapies, called "AVC-Boosters". Our first-in-class product platform is designed to deliver targeted and potent immune-modulating treatments for patients with cancer or auto-immune diseases.

Batavia Biosciences is a science-based CDMO that offers personalized services that fully support all the stages of biopharmaceutical development, from cloning to GMP manufacture and release of clinical material for phase I/II studies. We are not your standard CDMO - our customers regularly refer to us as their product development partner and thought partner. We focus on the early stages of product development with services ranging from DNA cloning, mammalian cell line generation, upstream process development, purification development, product characterization to clinical manufacturing. Headquartered in Leiden, The Netherlands, Batavia Biosciences is privileged to have strong strategic partners in both the EU and US. Batavia Biosciences aims to significantly contribute to ease human suffering from infectious disease and cancer.

Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees.

BIMINI Biotech BV is an innovative biotech start-up that is developing unique compounds for oncology.

BiOraliX' proprietary formulation technology provides a new way to orally deliver biopharmaceutical therapies patient friendly and with superior bioavailability. For patients, self-medication is now within reach for the most complex biologics treatments, especially for chronic diseases such as rheumatoid arthritis, allergy and asthma.

With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

CardiacBooster is a medical device company with offices in Galway, Ireland and Nijmegen, Netherlands. A spin-off from the Radboud University Medical Center (Nijmegen, Netherlands), CardiacBooster is developing a minimally invasive cardiac support device.

Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.

Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers' needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek', our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.

Solvias helps innovative companies advance their path to commercialization with CMC analytical solutions powered by deep scientific expertise and a relentless focus on our customers' success. With years of expertise in small molecules, biologics and cell and gene therapies, our talented subject matter experts have the know-how, creativity, and tenacity to solve even the most complex analytical challenges. Solvias offers comprehensive solutions from raw materials to drug products to final release testing as well as API development and manufacturing for small molecules. Customers have a single, trusted analytical partner for their entire development journey. Our five global facilities are strategically placed in biopharmaceutical hubs. We are GMP, GLP and ISO certified and conduct over 100 successful customer audits every year. We take pride in putting science and quality at the heart of everything we do, helping our customers bring better and safer products to market faster.

Overview: Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus’ target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We have a pipeline of six productivity traits including traits for pod shatter reduction, disease resistance and nutrient use efficiency. Cibus' focus is multi-crop traits for the major crops: canola, rice, soybean, wheat, and corn. In other words, traits that can impact global agriculture sustainability at scale. Technology: Gene editing in agriculture is a plant breeding technology. The promise of gene editing in agriculture is the ability to develop plant traits that are indistinguishable from traits developed using conventional breeding but can be developed at a fraction of the time and cost. To many, gene editing represents agriculture’s “analog to digital” technology moment. It is a technology that changes the speed and scale of trait development. Cibus is at the forefront of this technology moment. Our Rapid Trait Development System™ (RTDS®) and Trait Machine™ process represents the first end-to-end semi-automated plant breeding system. Vision: Cibus’ vision is to be a pure play trait developer; a technology company whose business is to develop and license plant traits to seed companies in exchange for royalties. The licensing of plant traits and germplasm with quantifiable benefits and strong intellectual property is an integral part of the seed industry. Our goal is to be a leader in this segment of the seed industry.

Cimaas - Our mission is achieving a better cure for cancer. For this, CiMaas develops therapies engaging the immune system for the treatment of a steadily growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking away several of the severe side-effects of current therapies.

CimCure’s solution is a vaccination based immunotherapy directed to the tumor blood vessels that are common to most solid tumors.

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

CleanNA's focuses on supplying an evolving market with high quality products, providing the latest technology, high-efficiency and cost-effective magnetic bead-based kits for both DNA and RNA analysis. A dedicated team combines both scientific and technical knowledge providing an ideal interface between the user and life science application(s). Our proprietary magnetic bead technology delivers a high quality nucleic acid purification system, highly effective for cleanup of PCR and sequencing products for both Sanger Sequencing as well as Next Generation Sequencing. CleanNA offers magnetic bead-based solutions for DNA and RNA isolation from various sample sources, for example Whole Blood, FFPE, Plant tissue, etc. All our protocols are designed for high throughput nucleic acid purification and can easily be adapted on commercially available liquid handling instruments. Our proprietary chemistries can be applied in many markets including but not limited to sequencing core facilities in academic institutions, diagnostic centers, sequencing services providers around Europe and the world.

Complement Pharma is a biotech company developing new therapeutics that target the complement system, an important component of the immune system. With a focus on C6 we aim to fight neurodegeneration in indications like TBI, ALS and MS. Our promising pre-clinical data, shows safety and efficacy of C6 inhibition to modify disease progression in the mentioned indications and beyond. Our first antibody, with excellent characteristics is now getting ready for GMP production and clinical trials. In June 2018 Alexion and Complement Pharma announced their collaboration to develop C6 complement inhibitor CP010 for neurodegenerative disorders.

Cortalix is a clinical-stage biopharmaceutical company developing imaging diagnostics and targeted radiotherapeutics based on its proprietary single domain antibodies (nanobodies) platform. Cortalix developed a pipeline of radiopharmaceuticals that target fibrogenesis-related membrane receptors and proteins that appear in early stage fibrotic diseases such as in pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis and several solid cancers with fibrotic stroma, including colon cancer and pancreatic cancer. The Cortalix technology platform is based on the screening and selection of single domain antibodies for myofibroblast-specific membrane proteins and receptors including PDGFRA (CD140a), PDGFRB (CD140b), EGFR, IGF-2R (CD222) and FAP. Our nanobodies do contain a functional group that can chelate a radionuclide suitable for nuclear imaging. Eventually the platform allows for a theranostic approach in cancer using the same single domain antibody for patient identification, targeted therapy and disease monitoring (a combined diagnostic and therapeutic in 1 molecule). Cortalix wants to share its single domain antibodies platform, the selection of new candidate molecules from it and, if appropriate, the development of new radiopharmaceuticals with others and offers this knowledge as a service, whether or not under license.

We believe Cells can theoretically produce almost anything, from fabrics to food, fuel and medicines. Designing cell-factories is hard, but our tools and machine-learning models can make it easier. Our mission is to ultimately help replace traditional farms and factories for a more sustainable world.

Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr®. CliCr® has a higher stability, enables faster reactions, and generates optimal bioconjugate products. Our mission is to offer our CliCr® technology to partners under license agreements in different diagnostic and therapeutic areas.

Aberrant functioning of kinases is known to be an important driver in cancer. Targeting hereof has proven to be extremely successful and has already revolutionized the management of numerous types of cancer. At Crossfire Oncology we approach kinases from three different angles: inhibitors, degraders, and degrader antibody conjugates. This tailored approach allows us to design kinase targeting drugs that aim to maximize the therapeutic benefit for cancer patients.

CyTuVax develops therapeutic vaccines against cancer and protective vaccines against viral & bacterial pathogens for which there is a high medical need. The patient is at the core in our vaccine development in which we apply our powerful adjuvant platform technology.

DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of Alzheimer’s disease. Using Adeno-Associated-Viral (AAV) vectors we deliver genes in the brain that initiate the local production of therapeutic antibodies

DAB.bio develops and deploys cutting-edge fermentation technology. Our unique and patented FAST platform (Fermentation Accelerated by Separation Technology) enables continuous fermentation with cost reductions of 20-50% or more and is one of the most significant fermentation innovations of the past decade. The global focus on synthetic biology has delivered breakthrough routes to replace fossil-based chemicals with sustainable bio-based alternatives. High manufacturing costs currently hamper the large-scale manufacturing of many of these alternatives. FAST addresses this issue head-on. It is the largest contributor to lowering manufacturing costs and facilitating large-scale deployment of bio-based chemicals. DAB.bio promises a significant impact.

Digi.Bio is bridging the digital and biological world through microfluidic automation and AI. We develop programmable microfluidics platforms, integrated with sensor and AI, to make biology easier to engineer.

ENPICOM is an innovative bioinformatics software engineering company committed to accelerating biologics discovery and development through cutting-edge bioinformatics solutions. With a deep understanding of biology, software engineering, and AI, ENPICOM delivers innovative tools that empower scientists to make groundbreaking discoveries faster and more accurately. For more information visit enpicom.com.

We are Erasmus MC. Our roots lie in Rotterdam, a city and port of international standing. We are the most innovative university medical center in the Netherlands and one of the world’s leading centers of scientific research. We are committed to achieving a healthy population and pursuing excellence in healthcare through research and teaching. Day in, day out, our staff, volunteers and students work with passion and dedication to achieve everything we stand for: safe, first-rate healthcare for patients with complex issues, unusual and rare conditions or acute needs. But we also stand for top-quality teaching that attracts ambitious, inquisitive and talented students and seeks to answer the healthcare questions of tomorrow. And we stand for world-class scientific research that bolsters our understanding of diseases and disorders and helps to predict, treat and prevent them. We do our work based on our basic principles, the core values of Erasmus MC, 'responsible'​, 'connecting'​ and 'enterprising'​. We believe that we provide the best care, research and education if we are responsible, binding and enterprising.

EV Biotech is a biotechnology company that creates microbial production platforms for high-value chemicals and proteins. Our so-called microbial cell factories (MCFs) provide effective, bio-based alternatives to conventional chemical-synthetic, fossil fuel-dependent production processes. MCFs can produce sustainable, bio-based compounds for different target markets including Flavours & Fragrances, Biomaterials and Pharmaceuticals. Unique to EV’sapproach is the use of computational modelling and microorganisms. By combining classical fermentation methods with the latest developments in modelling approaches we have revolutionised the methods of microbial strain engineering.

Development, production and marketing of high end industrial two- and threephase dynamic settlers. The main international fields of application are algae harvesting, dewatering and removing (ultra)fines from Oil Based Mud. Machines are sold worldwide.

Fagron is committed to the personalization of health treatment to cover the individual patient's need through Pharmaceutical Compounding & Sterile Outsourcing Services. Pharmaceutical Compounding allows pharmacists and prescribers to create medication that satisfies patients' needs. Through our services towards personalization, we can extend the range of mass-produced medication and keep available medicaments that are no longer offered commercially in an affordable way for those who need them. Fagron was founded in the Netherlands in 1990 and is currently present in 35 countries worldwide enabling pharmacists, prescribers, hospitals, and industry to provide quality, safety, and service for their patients. Together we create the future of personalizing medicine.

Flindr Therapeutics B.V. is a precision oncology therapeutics company that is developing first-in-class small molecule inhibitors. The company has secured €20 million in Series A financing to advance its pipeline of precision oncology treatments.

New DNA technologies are rapidly being developed and will have an increasing impact on the world and on people's daily life. Future Genomics Technologies aims to translate academic knowledge and novel technologies into usable applications and provide early and easy access to these applications. Our mission is to help you achieve your goals using cutting edge sequencing and bioinformatics technology.

GC biotech, based in Waddinxveen, the Netherlands, distributes a wide range of life science products. The emphasis lies on instruments, software, kits and reagents, developed with the aim to simplify, accelerate and improve life sciences research. GC biotech combines the representation of some of the most advanced US and EU suppliers with in-house scientific and technical know-how. Since November 2012 GC biotech is ISO 9001 certified, that reflects the company's continued commitment to the highest quality standards. Over the years GC biotech has built a strong sales team with academic backgrounds in molecular biology. They are supported by an engineering team with years of experience in instrumentation and software.

GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. We combine our renowned software and reagents for high resolution HLA typing by Next Generation Sequencing and Chimerism monitoring, with ex-cellent customer support and education. We work closely with our partners and clients and share knowledge to advance the field of trans-plant typing and monitoring. With a highly educated and motivated team of about 90 people and 40 distributors, we contribute to the quality of life of transplant patients worldwide.

Genetwister is an innovative Dutch biotechnology company founded in 1998 specialized in molecular breeding and bioinformatics of agricultural, horticultural and ornamental plants. Through our research projects we help our customers improve crop quality to enable more sustainable farming and a more reliable food supply for the future. Our shareholders are five internationally renowned vegetable and ornamental breeding companies we are proud to serve.

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

HAL Allergy is one of the European top players in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With all our activities the patient’s well-being is always our top priority. At our headquarters in the Leiden Bio Science Park (NL) we focus on the development and manufacturing of modified allergen extracts for the therapeutic and diagnostic purposes of respiratory and food allergies. At HAL Allergy, we foster open discussions, an entrepreneurial spirit and close collaborations within the teams and with our international colleagues. The HAL Allergy team sums up more than 300 highly specialized people across various functions. If you too would like to become part of an innovative and challenging pharmaceutical manufacturer, then this is a perfect opportunity! Join HAL Allergy & drive innovation!

Hercules Pharmaceuticals, Inc is a fully independent pharmaceutical wholesale distributor accredited and licensed by the National Association of Boards of Pharmacy (NABP) in all 50 states. They serve the full spectrum of pharmaceutical care, including retail, compounding, and specialty pharmacy. Hercules Pharmaceuticals is committed to providing high-quality pharmaceuticals and exceptional customer service to their clients.

HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoids. HUB´s Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides services its organoid biobank.

Hybridize Therapeutics is a spin-off from the Leiden University Medical Center and is a therapeutic company focused on developing kidney-protecting modalities for untreated kidney diseases.

Hycult Biotech is a Netherlands-based biotechnology company that specializes in research reagents and tools for complement system analysis and innate immunity research. Established in 1994, the company has over 30 years of experience in developing monoclonal antibodies, ELISA kits, and proteins aimed at advancing diagnostics and therapeutic research. Hycult serves as a trusted partner for academic, pharmaceutical, and biotech researchers, providing products to study immune-related diseases. The company emphasizes collaborative innovation, working closely with scientists worldwide to tackle challenges in disease monitoring and treatment. In 2019, Hycult enhanced its capabilities by acquiring Biocult, a specialist in monoclonal antibody production, which bolstered its contract manufacturing services. The company offers a range of products, including ELISA kits, monoclonal antibodies, and proteins, along with large-scale antibody production and support tools for data analysis.

By combining machine learning with advanced chemistry, inBiome enables microbiology labs over the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable- and antibiotics treated species are detected. Current applications include replacing traditional culture in ICU’s for more accurate, same day results, infection control, gut flora analysis and various r&d applications for healthcare, pharmacy and food industies. Promising new applications currently undergoing clinical trials include IBD and Sepsis dagnostics and preventive screening.

Innatoss Laboratories is a Dutch research intensive organization developing and performing in vitro diagnostics of infectious diseases such as Lyme disease, Q fever and recently COVID-19. With our lab facility located in the center of the largest Q fever epidemic worldwide, we are very aware of our goal: improve diagnostics to detect these infectious diseases as early as possible and rid the world of associated health problems, such as the chronic types of these diseases. Our passion, knowledge and drive will helps us to reach our goals and to assist those who are in need of innovative diagnostics and blood testing services. Recent assignments and achievements include CE certification of the first cell-mediated immunity test for Q fever (Q-detect), consortium membership of a Q fever vaccine development program led by Massachusetts General Hospital and an EU Horizon 2020 grant for the development of a cellular Lyme diagnostic test. We are open to new opportunities, collaborations and existing developments to bring diagnostic tests for infectious diseases to the next level.

InnoCore specializes in the formulation, process development, and manufacturing of long acting and minimally invasive injectable drug delivery products. InnoCore offers a unique and highly tunable polymer platform to control the delivery drug compounds, including small molecules (e.g. peptides and low solubles) and biologics (e.g. proteins and antibodies). Our proprietary polymer platform features a variety of benefits to your API's such as: - solving toxicity challenges - maintaining/increasing stability and structural integrity of sensitive compounds (e.g. by applying low temperature process conditions during manufacturing) - sustained release of of drug molecules from days up to at least 6 months - precise control over particle size (preventing absorption by macrophages and ensuring injectability) - ensuring smooth bioavailability - enabling the use of small needle sizes for patient compliance By merging developmental collaborations and licensing partnerships with our exclusive SynBiosys biodegradable polymer technologies, we generate innovative injectable and implantable drug delivery products. We invite you to navigate through our website and discover how we can enhance the performance of your device and/or drug and add value to your product pipeline.

InnoSIGN commercializes OncoSIGNal mRNA-based tests that measure the activity of signal transduction pathways in cancer and immune cells to predict how patients will respond to targeted drugs.

Chicken hatheries normally cull male chicks at an early age since they do not produce eggs. This company has developed technology that prevents hatcheries from having to cull male chicks. They use a proprietary biomarker, high-speed sampling,and mass spectrometry to identify the gender of a chicken before the egg has hatched. Eggs with male chicks can be destroyed, thus ensuring that male chicks do not hatch and will not need to be culled.

We are Insect School. We want to create a sustainable future for our children, by unleashing a chain reaction of people and companies contributing to global circular food production. Commercially growing the Black Soldier Fly is one of the most effective steps towards this circular food production. The BSF larva provides the best source of animal protein and is a high-quality food source for pigs, chickens, fish, and pets. Our goal is to make BSF farming as commercially attractive as possible to companies. And to increase our impact, we share our knowledge and experience. With Insect School, we make our expertise available to the whole world. Insect School is founded by Insect Engineers, which develops, builds, and supplies machinery and climate systems for the global BSF industry in feed. Solutions for the entire production process, from breeding to production and processing. Find out more on www.insectengineers.com

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies. As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans. Part of Utrecht Science Park Bilthoven

Iribov is an international plant breeding support laboratory founded in 1992, employing around 600 people in 3 locations: in The Netherlands (Heerhugowaard), Macedonia (Vinica) and Ghana (Sogakope). The services of Iribov can be divided into 4 segments: 𝗣𝗹𝗮𝗻𝘁 𝗧𝗶𝘀𝘀𝘂𝗲 𝗖𝘂𝗹𝘁𝘂𝗿𝗲: Initiation, Virus Elimination, Naktuinbouw Elite certified production, Stock Maintainance, Protocol Development, Large Scale Propagation. 𝗕𝗿𝗲𝗲𝗱𝗶𝗻𝗴 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: Gene Bank Storage in Tissue Culture, Interspecific crossing, Embryo Rescue, Mutation Induction, Dihaploid production, Polyploidization, Marker Assisted Breeding, Crispr-Cas (future development). 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀: Plant pathogen detection (PCR), Seed quality control, Flowcytometry, Cytology, Biochemical Assays, Bioassays. Hardening: automated planting of tissue culture plants, vertical farm facilities, automated grading and sorting, various growing compartments and -specifications, tailor made growing solutions. The portfolio of Iribov covers over 450 plant species in 10.000 varieties for the ornamental horticulture, vegetable and (soft)fruit companies and the plantation industry worldwide.

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. SLP®immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP®lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP®immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases. ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV. The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com SLP® and AMPLIVANT® are registered trademarks in Europe.

Jeta's mission is to improve outcomes for transplant patients by providing the highest quality medical devices available. These tests will provide best in class solutions for post-transplant surveillance of disease relapse, as well as organ and stem cell transplant rejection. Jeta's systems will enable new applications, lead to improved laboratory workflows, lower per test costs and will ideally translate into better patient care and survival rates

Kaleido is an award-winning, enterprise-grade Web3 platform making blockchain and digital assets radically simple for organizations to adopt. Kaleido provides security, compliance, and scalability for the most stringent enterprise requirements within highly regulated industries. Kaleido’s platform is ISO27K and SOC 2 Type 2 certified with built-in high availability and disaster recovery, achieving 99.99% uptime over the past 5 years.

We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases

Kling Biotherapeutics is a clinical-stage, privately held biotech company focused on discovery and development of antibody based therapeutics. The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells. Kling-Select relies on a fully-owned and well-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralising antibodies for various infectious diseases such as RSV (Nirsevimab/Beyfortus), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches. Kling-Evolve enables the in vitro maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets. In addition to platform technologies, Kling Biotherapeutics is pursuing asset pipeline programs with KBA1412 currently in phase I, and multiple programs in preclinical development.

Kyazma® focuses on genetic linkage analysis in diploid experimental populations.

Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Lead Pharma is a clinical-stage pharmaceutical research and development company located in Oss, Netherlands. A spinoff from the Hubrecht Institute and the University Medical Center Utrecht, it focuses on discovering and developing innovative small-molecule therapies for autoimmune diseases and cancer. The company operates from Pivot Park, a biopharmaceutical life sciences campus, equipped with labs for all stages of drug discovery, including medicinal chemistry and pharmacology. The management team includes CEO Frans van den Berg and Chief Scientific Officer Arthur Oubrie, supported by a skilled workforce of 29 employees, many of whom have advanced degrees. Lead Pharma is committed to innovation, with a pipeline of oral therapies designed for efficacy and safety. The company actively pursues partnerships, including a collaboration with Roche to develop treatments for immune-mediated diseases. Lead Pharma has raised $11.86 million in funding and holds 10 patents, emphasizing its focus on advancing science in the pharmaceutical sector.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells. Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail. Our goal is to advance science and improve human health, by providing tools that unlock the measurement of forces and interactions in biology. For the first time ever, our unapparelled solutions can assist research by directly linking structural and ‘omics analysis to functional outcomes at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.

Mair Therapeutics is a preclinical-stage drug discovery company focused on the discovery and development of a small-molecule ion channel activator to treat Parkinson's disease.

Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development program is the development of a medicine to fight sepsis and septic shock, which is currently in clinical phase.

Molecular Biology Systems, B.V., founded in 2015, is a molecular biology solutions company based in the Netherlands. Our NextGenPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycling times from hours to minutes. These technological advances support laboratories across the life sciences market, reduce costs and accelerate processing times. NextGenPCR, the amplification technology of the future, now available.

Meatable makes 100% real, delicious, guilt-free meat. With one cell, we are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time we increase food security, without compromising the culinary experience of eating tasty, real meat.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Modra (Modulated Oral Drug Absorption) Pharmaceuticals B.V. is a spin-out from two internationally acclaimed centers of excellence in oncology, the ‘Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)’ and the MC Slotervaart (Slotervaart) in Amsterdam. Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability of existing anticancer drugs, “the iv to oral switch”, to improve cancer therapy and supportive care. Modra Pharmaceuticals has several products in preclinical and clinical development including oral formulations of docetaxel and paclitaxel.

MolGen is a total solutions global supplier of innovative extraction DNA / RNA technology, system, products and kits for human and animal diagnostics, agriculture and biotech.COVID-19: (-6/21) partnership with SpeeDx on COVID-19 testing.

In 2013, our Chief Scientific Officer Professor Mark Post unveiled the world’s first cultured meat hamburger to a packed press conference in London. The burger was harvested directly from cow cells, rather than raising and slaughtering a whole animal. It was the result of years of research at Maastricht University, and cost €250,000 to make. The effort was funded by Sergey Brin, the co-founder of Google. Our motivation was to find a new method to make real meat to feed our fast-growing population in a sustainable, healthy and animal-friendly way. Following the success of the first hamburger, we created Mosa Meat to commercialise cultured meat (also known as clean meat, cultivated meat or cell-based meat) and bring it to plates everywhere. In the past few years we’ve made significant scientific breakthroughs, and brought the price down considerably. We’re now focussed on scaling up the production process, and getting our first products to market.

The Netherlands Center for the Clinical advancement of Cell and Gene Therapies (NecstGen), situated in Leiden, comprises of a state-of-the-art facility and expert knowledge for the development, production, and commercialization of Cell and Gene Therapies. NecstGen helps academic and industrial Cell & Gene Therapy developers to enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC and regulatory affairs in a brand new 4,000 m2 development & GMP manufacturing facility. We enable the next generation of therapies by translating research programs into actionalbe health solutions for patients. Our service offering: A flexible Cell and Gene Therapy manufacturing model - Full contract manufacturing services by our expert team for Cell Therapy and Viral Vector - We manufacture Pre-clinical or toxicology study material, Phase I, Phase II clinical trial material - GMP rental for any mammalian cell-based therapy type, including Cell and Viral Vector based therapies - QC, QA, and QP services supporting our cleanroom rental - Hybrid support on a flexible basis where our team compliments yours Process and assay development for Cell Therapies and Viral Vector - Process design and optimisation - Scale-up to clinically relevant volumes - Automation and closed processes - Assay development for in-process controls, release- and potency tests - Technology transfer in and out with flexibility in-mind for the future progress of your manufacturing - Consultancy-based work to advise on decision making Talk to NecstGen today about your needs for: - Induced Pluripotent Stem Cells (iPSC) - Chimeric Antigen Receptor T-Cells (CAR-T), Tumor Infiltrating Lymphocytes (TIL) T-Cell Receptor Modified T-Cells (TCR-T) - Natural Killer (NK) Cells/CAR-NK Cells - Dendritic Cells (DC) - Mesenchymal Stromal Cells (MSC) - Lentivirus (LV) - Aden-associated virus (AAV) - Oncolytic viruses - Cleanroom rental for any mammalian cell-based therapy type

Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

NewAmsterdam Pharma - Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating Obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy. In January 2021, NewAmsterdam completed its Series A funding round of $196M (€160M) which will support the full Phase 3 development of Obicetrapib.

ニコンは、100年の歴史で培ってきた「光利用技術」と「精密技術」をもとに、多彩な技術・製品・サービスをグローバルに展開しています。 映像の可能性の追求から、スマートデバイスやバイオサイエンスの進化、高度なものづくり、さらに数十億光年彼方の宇宙を捉える挑戦まで。世界中の人々の暮らしを、未来を開く最先端産業を、そして人類の挑戦を、ニコンはこれからも支え続けます。 At Nikon, we use opto-electronics and precision technologies cultivated during our 100-year history to provide a wide range of products and services globally. Our activities extend from exploring the possibilities of imaging, to advancing bioscience and smart devices, refining our high-level manufacturing processes, and capturing views of stars that are billions of light years away. Nikon will continue to enrich lives, support cutting-edge industries that are shaping the future, and confront challenges around the world.

- Our DNA - NimaGen, part of the Dutch Biolegio Holding and founded in 2011, is a well-recognized ISO certified manufacturer and vendor of reagents and workflow solutions for Sanger Sequencing and Next Generation Sequencing (NGS). We serve molecular biology laboratories around the world, active in human genetics, forensics, microbiology and infectious disease. - Our Mission - NimaGen’s mission is helping laboratories create value for their customers, through proven and cost-effective workflows, providing detailed insights and enabling informed decision making. From clinical research to forensics to agriculture to food safety and environmental hygiene. - Patented Core Technology - Our core technology, Reverse Complement PCR (RC-PCR), provides the most safe, swift and simple worklow for NGS Library Prep. It comprises simultaneous multiplex target amplification and NGS indexing or barcoding in a single, closed tube PCR assay. Compatible with illumina® and Oxford Nanopore Technologies®. - Sanger Sequencing Workflow Reagents - We are the globally recognized provider of a complete workflow portfolio of drop-in reagents for 3130, 3500, 3730 and SeqStudio™ Genetic Analyzers. From PCR purification to dyeterminator reaction cleanup and running samples, to safeguarding capillary operational life span. For DNA sequencing results and data you can trust. - Featured Brands - EasySeq™, IDseek®, BrilliantDye™, NimaPOP™, NimaPrime™, D-Pure™, iX-Pure™, ExS-Pure™, Alpaqua®, AmpliClean™, Biolegio. - Further Information - Please contact NimaGen’s resourceful specialists: • E-mail: info@nimagen.com • Website: www.nimagen.com; www.rcpcr.com • Instagram: @nimagen; LinkedIn: @NimaGen

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology). We have established deep roots throughout Europe, and more recently, expanded outside of Europe, with the creation of an affiliate in Canada. Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care. Nordic Pharma's values of Commitment, Ambition, Respect, Reliability, Integrity and Agility describe our culture and standards and guide us in our way of working.

By applying nanotechnology, photonics and machine learning, Nostics brings a new type of diagnostics to a world desperately in need for 21st century solutions. We believe that a good life starts with good health. We believe that accessible and affordable diagnostics should be a given for our entire human family. Improvements in healthcare can only start when we know what’s going on. By providing instant and affordable testing at any location, Nostics wants to contribute to a better safer and healthier world.

Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues. We leverage nature's own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery. Welcome to the next frontier of medicine. Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy. We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies. The mission of NTrans Technologies is to become the leading non-viral delivery platform in cell and gene therapy. Please contact us at: info@ntranstechnologies.com

At Oncosence we target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

Ophtec is a family-owned company founded in 1983 by Prof. Dr. Jan Worst and Anneke Worst-Van Dam. Based in the Netherlands, it is a global leader in intraocular lens (IOL) innovation, specializing in solutions for cataract and refractive surgery. With a focus on pioneering ophthalmic products, Ophtec has recently modernized its brand while celebrating 40 years of excellence in the field. The company offers a range of products, including monofocal, toric, and presbyopia-correcting cataract IOLs, as well as the Artisan lens, the first iris-fixated IOL for refractive correction. Ophtec is also developing new innovations, such as the ArtiPlus lens and pre-loaded injector systems. In addition to its product offerings, Ophtec provides surgeon training and clinical support, collaborating with ophthalmologists to enhance surgical techniques and outcomes. The company is dedicated to empowering eye surgeons to deliver high-quality vision results, particularly in complex cases.

Orexa is a phase 2 pharmaceutical company that develops and commercializes therapeutics to increase food intake. Its lead compound ORE-001 is a proprietary oral formulation, based on a well known anesthetic. The company has started its first phase 2a study in the Prevention of Post-Operative Ileus. Furthermore it is in preparation for phase 2a studies in Anorexia and Cachexia. With these three indications increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings. Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands. Attractive risk/reward: • Lower risk, because the active substance is already well known for many decades; • Lean and fast development plan; • Very attractive market potential. Strong patent portfolio: • Broad claims for all local anesthetics to increase food intake after both single and repeated administration; • Well understood mode of action; • Novel mode of delivery, with a proprietary oral formulation. We are looking for partnerships with: ★ an experienced mid or big pharma company with a focus on 505(b)(2) applications for the late stage clinical development and for the marketing in the US & EU markets (and possibly more); ★ a suitable Chinese company with experience in phase 2 & phase 3 clinical trials and an effective sales channel in the majority of the Chinese market; ★ a large scale specialized animal food company or a large veterinary drug company for the veterinary applications. We’d love to hear from you. We’ll get back to you as soon as we can! You can contact us at info@orexa.nl.

PamGene is a functional proteomics Company with a unique 3D array platform to measure the ACTIVITY of Tyrosine and Serine/Threonine kinase. We offer Products (described in our Showcase pages, PamStation-12 ®, Pamchip arrays ® and Reagent kits) and Services (lead optimization, translational/ preclinical research and biomarker discovery). We have developed powerful software tools (BioNavigator) for complex data analysis with which you can interpret results in a biological context. We support clinical trials in the oncology area. Pamgene is advancing research in Oncology as well as other areas (Neurobiology, Immunology, Metabolic disorders, cardiovascular respiratory diseases). Our technology has a wide range of Applications from fundamental and discovery research to clinical development of therapeutic and diagnostic biomarkers. Our patented technology stands out in allowing scientists in industry and academia to measure enzyme activity within a cellular context and fully decorated proteins. The assays have high sensitivity, broad kinome coverage and works for many sample sources. PamGene has a strong science foundation and the number of publications applying our technology continues to rise. PamGene's Customer Service team supports your research with dedication. The PamAcademy offers advanced training, from workflows to data analysis, interpretation and storage. PamGene's PamCloud space allows User-interaction and furthers knowledge exploration. Please visit our web site for further information (https://www.pamgene.com/) and get in touch with us! (https://www.pamgene.com/en/landing.htm)

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

Pantarhei Bioscience BV (PRB) is a company in The Netherlands with an innovative concept of drug development in Woman’s Health. PRB's wholly owned subsidiary company – Pantarhei Oncology (PRO) (http://www.pantarheioncology.nl) develops innovative treatments for Endocrine Cancer. PRB and PRO have developed a product pipeline based on the proven ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are and in oncology breast cancer, prostate cancer and ovarian cancer. The business concept of PRB and PRO is to develop the patented new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model is based on solid patent protection, internal project management and external research and development activities. Intellectual property (IP) and data supporting the new treatment concepts are licensed out for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

OUR NUTRIENT DRUG CONJUGATE TECHNOLOGY (NDCt)™ - turns parenteral compounds into oral variants or improves oral bioavailability. - uses specific transporter proteins for food, i.e. active transport over the gut wall. - delivers tailor made solutions with our toolbox of linkers and nutrient. PATIENTS BENEFITS: - Oral administration is by far the preferred route and GI side effects may diminish, both improving compliance and with that efficacy - Enhanced bioavailability gives less inter-patient variability - New indications for the same compound BENEFITS TO COMPANIES: - Life cycle management from an NCE (new IP, often COM). - Short route to approval. - NDCt platform broadly applicable, irrespective of disease area. - Accelerate development of pipeline products. - Once promising, but now shelved research, can be revived. NDCt GIVES CONTROL OVER THE COMPOUND We chemically attach a nutrient mimic via a linker to the drug. The linker has profound effects on transport and synthesis. The nutrient mimic is a transporter substrate – recognized by the intestinal wall – facilitating active transport (vs passive transport of old-fashioned drugs). Subsequent enzymatic cleavage in the bloodstream, liberating the drug. With our patented NDCt we address the full spectrum of issues around oral bioavailability and control the compound. PROVIDING THE MISSING LINK PharmaCytics developed a toolbox of proprietary linkers and nutrient mimics. With our bifunctional linker variants it is even possible to couple drugs to biomolecules, such as proteins and antibodies. In addition, our linker technology can produce mutual prodrugs (or codrugs) in which two different synergistic acting pharmacological agents are linked together. LET US REVIVE HIDDEN TREASURES IN YOUR PIPELINE PharmaCytics brings in its expertise on medicinal chemistry, prodrug technology and drug delivery to solve and improve on your drug development issues. CALL US AND CHALLENGE US!

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations.

Pleco Therapeutics is a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the cancer microenvironment. Their Plecoid™ therapies positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals.

We are ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases. We focus our drug development mainly on a group of blinding disorders affecting the retina, called inherited retinal diseases.

ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins. ProteoNic's 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings. The technology has wide ranging potential to boost production efficiencies in other important applications, including viral vector production, protein production in yeast and technologies which impact product quality. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market.

QurieGen (est. April 2022) aspires to revolutionize drug discovery. This biotech startup leverages a proprietary method of mapping cellular responses to drug stimuli. Uniquely, this disruptive technology reveals the full picture of the signaling pathways, replacing many different, mutually incompatible analytical tools that at best provide an incomplete picture of the cell response to drug perturbations. The QurieGen R&D team will build a unique AI platform to predict cellular responses to drug candidate molecules, enabling data-driven discovery. Currently, we are raising seed investment to accelerate our operations. Please contact us if you are interested in investing in QurieGen.

Qurin Diagnostics is developing diagnostic technology platform for noninvasive testing. Current developments are focused on advanced biochip technology suitable for multiple biological and biomedical applications.

RIBOPRO is an innovative service provider, producing high-quality, high-performance RNA products, which are used as powerful research tools and therapeutics. RiboPro offers both off-the-shelf and custom RNA products at competitive rates and turn-around times, effectively removing all barriers to successful use of RNA in the research and development of our customers. We have more than 2 years experience satisfying the RNA-related needs of our (returning!) customers and thus we are confident that we can help you get your next project off to a good start. Let us worry about the quality and performance of your RNA, so you can focus on your next success.

Rijk Zwaan develops vegetable varieties and sell the seeds produced from them to growers all over the world.

Over the past decade we have transformed into a focused leader in health technology. At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. We aim to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. We see healthcare as a connected whole. Helping people to live healthily and prevent disease. Giving clinicians the tools they need to make a precision diagnosis and deliver personalized treatment. Aiding the patient's recovery at home in the community. All supported by a seamless flow of data. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better. Visit our website: http://www.philips.com/ Follow our social media house rules https://www.philips.com/a-w/about-philips/social-media.html

Sairopa develops novel treatments for cancer by modulating the patient’s immune system. Early 2021 Sairopa acquired, backed by a reputable biotech investor, a portfolio of therapeutic antibodies from an American public company. Sairopa will enter clinical testing of two of its lead compounds in Phase 1 clinical trials in 2022. The company is based in Rotterdam, the Netherlands but operates internationally & virtually. To advance our programs, we are looking for a project manager that wants to make a difference and has a pioneer’s mentality.

Salvia BioElectronics is pioneering neuromodulation therapy aiming to transform the migraine treatment landscape. Designed to provide meaningful relief, MySalvia Therapy features an ultra-thin implant that comprehensively targets key nerves involved in migraine. ‍Salvia is driven by the belief that people with chronic migraine deserve the opportunity to reclaim their lives. Founded in 2017 and headquartered in Eindhoven, The Netherlands, Salvia is led by a team of industry veterans with extensive experience in medical devices and neuromodulation. Active in the United States, Europe and Australia, the company is advancing clinical development with the support of leading investors. Salvia is also exploring the potential of its technology for the treatment of cluster headache.

Met een community van duizenden medewerkers en honderdduizenden donors staat Sanquin middenin de maatschappij. Dagelijks wordt er vrijwillig en onbaatzuchtig bloed of plasma gedoneerd dat wordt verwerkt tot levensreddende bloedproducten en geneesmiddelen voor kwetsbare patiënten. Sanquin zoekt ook naar innovatieve oplossingen voor medische aandoeningen die nu nog niet (goed) te behandelen zijn. En spant zich in internationaal verband in voor de kwaliteit en optimaal gebruik van bloedproducten wereldwijd. Dit werk doen wij dagelijks met ongeveer 3000 werknemers. Onze verschillende werkgebieden zijn onderverdeeld in de volgende organisatie onderdelen: • Bloedbank • Diagnostiek • Research • Sanquinnovate • Sanquin Academy Nergens anders ter wereld komt de medische, farmaceutische en wetenschappelijke wereld zo evenwichtig bij elkaar in één innovatieve organisatie als bij Sanquin. Werken bij Sanquin doe je dan ook in een unieke werkomgeving. Kijk voor meer informatie over de verschillende werkvelden en de beschikbare vacatures op http://werkenbijsanquin.org Ben je geïnteresseerd in het donorschap, kijk voor meer informatie op http://www.sanquin.nl of doe de donortest op https://www.sanquin.nl/donortest/aanmelden Wil je samenwerken met ons, kijk dan op https://www.sanquin.org

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication. Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.

Scinvivo enables optical biopsy for bladder cancer diagnostics. Current imaging techniques for bladder cancer have their limitations, as they only enable the urologist to visualise the bladder wall surface. In 30% of the cases, healthy tissue is incorrectly classified as cancerous. Another limitation is that it is difficult to fully remove a tumor during a surgical procedure, as the borders of the tumor are difficult to visualize. The last limitation is that it is impossible to determine the invasion depth of the tumor with current imaging technologies, while the invasion depth has major impact on the proposed treatment. All these limitation lead to unnecessary, invasive, and costly interventions. Scinvivos technology enables the urologist to improve diagnosis, and thus decreasing the amount of interventions, patient burden, and costs.

Develops the scopeDx ® platform, a technology that uses proprietary Type III CRISPR-Cas nucleases to detect nucleic acid sequences

The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company's main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types. HPV-Risk Assay The HPV-Risk Assay is an in vitro real-time PCR-based assay The HPV-Risk Assay is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA, targeting the E7 region of the following 15 (probably) high-risk HPV genotypes, i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, and 68. The QIAsure Methylation Test The QIAsure Methylation Test is a real-time PCR-based molecular assay The QIAsure Methylation Test is a real-time PCR-based molecular assay to distinguish women with cervical (pre)cancer. The QIAsure Methylation Test specifically detects women with a cancer-like methylation profile that have a short term high risk for progression to cervical cancer.

SERDA Therapeutics is a biopharmaceutical company that develops a wound debridement solution specifically designed to treat severe burn injuries and persistent ulcers such as pressure ulcers.

Shandong Biotech is a fully-integrated biopharmaceutical company, specializing in the research & development, manufacturing and commercialization of therapeutic products.

Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. The company is a spin-off of the Netherlands Cancer Institute, where researchers recognized the need to simplify and improve localization technology for the surgical removal of breast cancers. This led to the development and clinical demonstration of the first magnetic seed localization, a technique that Sirius Medical perfected and further developed into the Sirius Pintuition System. Today, Sirius Pintuition represents the next generation of tumor localization technology, known as Surgical Marker Navigation. Pintuition is the only wire-free localization technology designed to provide navigational guidance in an easy-to-use and intuitive system. Its state-of-the-art GPSDetect™ software and unique TargetLOC™ feature provide real-time directional guidance using audio and visual feedback for unmatched precision to locate tumors more efficiently and accurately. The Pintuition platform is simple, precise, and accurate, delivering a better experience for patients and physicians. The CE-marked and FDA-cleared system is currently available in over 200 centers in the United States and western Europe.

Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.

Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.

Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation, and delivery of a wide range of complex and custom-designed assays. With a team of 150 across five global laboratory locations; Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA), we provide innovative solutions to support our customers to achieve their clinical milestones. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies. We pride ourselves on our deep scientific expertise and our ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and ultimately better management and treatment of human health. Synexa, improving the quality of human health through innovative biomarker and bioanalytical solutions.

Syngle Therapeutics is focused on developing an immunotherapy for the treatment of Parkinson’s disease. Syngle possesses several antibodies against oligomeric alphasynuclein, the main toxic species in Parkinson pathology.

Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. We are headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.

TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.

A clinical-stage biotechnology company pioneering a female-focused precision medicine approach using validated biobanks for the discovery, development, and commercialization of novel therapeutics and companion diagnostics in women's health.

Develop diagnostic tools for screening of diseases through exhaled breath.

The Hyve is the data & informatics service provider for life science organizations looking to align their data infrastructure with their research needs. We provide services regarding biomedical informatics solutions to most of the top 20 biotech and pharmaceutical companies, hospitals, universities, and medical centres in the United States and Europe, including Dana Farber Cancer Institute in Boston and King’s College London. We also collaborate with biobanks, registries, and patient organisations around the world. Our mission is to enable open science by developing and implementing open-source solutions and FAIRifying data in life sciences. We have ample experience with open-source tools such as cBioPortal, Open Targets, OHDSI/OMOP, RADAR-base, and Fairspace. The Hyve can also advise on practical application and implementation of the FAIR data principles, including semantic modelling, data landscaping, and knowledge graph creation.

Thirona is a global company based in Nijmegen, the Netherlands, that specializes in AI-powered medical image analysis, focusing on lung and retina images. Founded in 2014, Thirona combines medical science with artificial intelligence to deliver advanced solutions for clinical trials, treatment development, and personalized patient care. The company offers high-precision quantitative analysis of medical images, including lung quantification software that analyzes chest CT scans for lung disease detection and treatment planning. Their services also include the quantification of anatomical volumes, mapping of parenchymal disease distributions, and analysis of airway and vascular morphology. In addition to lung analysis, Thirona provides retina image analysis solutions, such as iCare RETCAD, which detects conditions like diabetic retinopathy and glaucoma. Thirona collaborates with clinical research organizations, multinational MedTech companies, and professionals in interventional pulmonology, supporting over 600 clinical sites in more than 40 countries and contributing to over 200 scientific papers.

More specifically, Trajectum Pharma is developing novel mRNA-based products, formulated as lipid nanoparticles for the field of rheumatoid arthritis and other inflammatory diseases. Trajectum Pharma is developing a potentially curative, first in class treatment, for which initial proof-of-concept for the treatment of RA has been established.The initial results in preclinical disease models are extremely promising. The long-term vision of the company is to develop an off-the-shelf vaccine for RA, using the principle of tolerance induction. The company has strong ties with Utrecht University, Department of Immunology and Infectious Diseases, Faculty of Veterinary Medicine (Prof. Femke Broere). There is an ongoing co-operation in the field of mRNA technology and lipid nanoparticle formulations with the Weissman Lab at UPenn (Philadephia, PA) (Prof. Drew Weissman).

Treeway is a clinical-stage biotech company developing therapy for ALS, Alzheimer's Disease and other neurodegenerative diseases. Treeway has been formed by the words tree of life and pathway of a disease, for the founders the symbolic way towards a cure. We foresee that medication, research and care will change dramatically in the coming decades and patients will become an essential part of this process on their pursuit for cures in rare and common diseases. Everyone can make a difference and our slogan "one man can and will find a way, why not be that man?"​ underpins our drive.

Uneedle realises a proprietary microneedle platform "Bella-mu" and "Bella-Vue", co-developing intradermal & suprachoroidal administered medicinal products with pharmaceutical partners. Uneedle is the legal manufacturer of this superior - short lumen - delivery platform. The single, hollow "Uneedles" are FDA approved and CE marked for direct application in the clinics worldwide.

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020. This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases. With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy. Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022. We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow. We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than 13,000 real-world implantations. As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.

VHLGenetics is a leading service provider with three business units: in The Netherlands Dr. van Haeringen Laboratorium B.V. (VHL), in Germany Certagen GmbH and in Belgium Dr. van Haeringen Polygen bvba (VHP). For more than 25 years, DNA has been the core of the organization, serving customers with routine DNA tests in non-human species. Utilizing the latest DNA technologies has enabled the VHLGenetics to grow quickly since 1993. Nowadays, our experienced laboratories offer more than 500 routine DNA tests for animals, plants and microorganisms. A few examples of routine tests in the portfolio of VHLGenetics include parentage verification, genotyping genetic traits like causal mutations, coat variation and the detection of pathogens (ParaTBC or QFever). For more information, please visit our website at www.vhlgenetics.com.

Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico is initially targeting spinocerebellar ataxia types 3 and 1 and Huntington’s disease. Our VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA.

ViroNovative BV, established in 2002, is dedicated to providing a complete solution to human Metapneumovirus (hMPV), a virus discovered in 2001 at the Department of Viroscience, Erasmus MC. To this end, ViroNovative is co-developing diagnostics, vaccines, antibodies and antivirals for the detection, prevention and treatment of hMPV infection. With a strong network of industrial partners (to date 20 licenses on the hMPV patents are active) we generate new products and economic value.

Vitestro will be the first to bring autonomous blood drawing technology to European hospitals. Blood drawing, performed billions of times per year worldwide, is key to clinical diagnosis. Given a growing population and shortages of healthcare personnel, there is a clear need for a future-proof system to keep up with demand for diagnostics.

We’re an innovative ingredients company making the potential of precision fermentation a commercial reality. We create superior dairy proteins with significantly less impact on the planet. OUR PURPOSE To make the promise of dairy protein from precision fermentation a commercial reality in order to meet the world’s growing need for nutritious, functional and sustainably-produced proteins. OUR WAY OF WORKING We create superior dairy proteins so that our customers can develop delicious products that are highly nutritious, functional and with an improved environmental footprint. We bring a deep understanding of our customers’ needs across the total value chain to our partnerships every step of the way, from our application know-how through to our supply-chain excellence. OUR FUTURE Our global food system must radically transform to meet the world's growing need for protein in a sustainable and resilient way. This requires new sources of highly nutritious and functional proteins which are significantly less demanding on our environment. With the dedication and hard work of industry experts precision fermentation will become a scalable and viable reality, leaving a better planet for future generations. WORK WITH US We want to work closely with all innovative food & beverage players who believe their brand could benefit from a more sustainably-produced & ethically-sourced yet highly functional ingredient. OUR PRODUCT Our whey protein from fermentation is available for customers now, with self-affirmed GRAS in the USA. It’s pure in beta-lactoglobulin, abundant in leucine and BCAA's, has versatile functionality, clarity in solution, and is neutral inflavor. For further information about Vivici's innovative dairy proteins from fermentation or to explore partnership opportunities, please send a message here on LinkedIn or visit us over at vivici.com.

VIVOLTA is the healthcare industry's trusted partner for contract development and manufacturing of electrospun medical products that guide the body to heal itself. Founded in 2008, we leverage our proud heritage as high-performance electrospinning equipment designer now as a leading CDMO for electrospun medical devices and drug delivery systems.

Wageningen University & Research provides education and generates knowledge in the domain of healthy food and living environment. ‘To explore the potential of nature to improve the quality of life'. That is the mission of Wageningen University & Research (WUR). A staff of 6,500 and 10,000 students from over 100 countries work everywhere around the world in the domain of healthy food and living environment for governments and the business community-at-large. The strength of WUR lies in its ability to join the forces of specialised research institutes and the University. It also lies in the combined efforts of the various fields of natural and social sciences. This union of expertise leads to scientific breakthroughs that can quickly be put into practice and be incorporated into education. This is the Wageningen Approach. The scientific quality of WUR is affirmed by the prominent position we occupy in international rankings and citation indexes.

Winclove Probiotics, quality of life with probiotics Since 1987, Winclove Probiotics has specialized in the development and production of probiotics. We work with passionate business partners, leading universities, various research institutes and university hospitals around the world to develop effective indication-specific probiotics. Aiming for long-lasting, sustainable and strategic partnerships, we not only offer innovative, high-quality and competitive probiotic solutions but also share our scientific knowledge as much as possible. At Winclove Probiotics, commitment, drive and optimism are important. Our Great Place to Work certification also shows that we have a company culture of humanity, diversity and trust. Since 2020, we have been part of the B Corp community, joining forces with like-minded companies to protect our planet and contribute to a sustainable economy. Together, we are using ‘business as a force for good'. -- Winclove Probiotics, kwaliteit van leven met probiotica Sinds 1987 is Winclove Probiotics gespecialiseerd in de ontwikkeling en productie van probiotica. Wij werken met gedreven businesspartners, vooraanstaande universiteiten, uiteenlopende onderzoeksinstituten en (universitaire) ziekenhuizen wereldwijd om effectieve indicatiespecifieke probiotica te ontwikkelen. We streven naar langdurige, duurzame en strategische partnerships waarbij wij niet uitsluitend innovatieve, hoogwaardige en concurrerende probiotica-oplossingen bieden, maar ook zoveel mogelijk onze wetenschappelijke kennis delen. Bij Winclove Probiotics zijn betrokkenheid, gedrevenheid en optimisme belangrijk. Ons Great Place to Work-certificaat toont tevens aan dat we een bedrijfscultuur van menselijkheid, diversiteit en vertrouwen hebben. Sinds 2020 zijn we onderdeel van de B Corp-community en bundelen we met gelijkgestemde bedrijven de krachten om onze planeet te beschermen en bij te dragen aan een duurzame economie. Samen gebruiken we ‘business as a force for good.'

🌱 Enjoy Handsfree Plant Production & Plant Research At WPS, we are experts in crafting, implementing, and delivering cutting-edge logistics solutions for the greenhouse horticulture industry. Our mission is to maximize your profits by providing innovative and comprehensive systems that redefine efficiency. 🤝 Customer Appreciation: Our success stems from the trust and appreciation we receive from our valued customers. We take pride in our vast knowledge, pragmatic approach, and unwavering professionalism, which drive us to exceed expectations and deliver outstanding results. 🌿 Ambitious Goals: Our ambition is clear - to continuously empower our clients with the tools they need to thrive in a competitive market. With a decisive mindset, we are committed to translating challenges into opportunities and unlocking the full potential of your greenhouse horticulture business. Join us on this journey of growth and success, and together, let's cultivate a greener future for greenhouse horticulture. #WPS #GreenhouseHorticulture #Efficiency #LogisticsSolutions #Innovation

XiltriX North America was established to make life sciences safer and more predictable through technology. We leverage 30 years of experience in safeguarding life science assets and equipment combined with robust and proven technology to revolutionize laboratory and environmental monitoring for life science industries in North America. XiltriX is the only life-sciences laboratory monitoring company capable of delivering real time alerting to prevent catastrophic equipment failures, streamlined reporting processes to comply with regulatory bodies and standards organizations, and a 24/7 monitoring team that keeps a watchful eye on operations when no one else is around. All day, every day, XiltriX acts as the pulse of your laboratory infrastructure, by protecting your science, giving you peace-of-mind and helping you sleep at night. Our system checks measurements in real-time from any number of sensors, assets, and equipment. It then logs the data securely in the cloud and generates public or personal alarms when any parameter deviates from set limits. The modular, network-based design means that it can be configured to meet any current need, with the ability to scale easily over time. XiltriX is not constrained by the physical structure of the laboratory, as data transmission can be wired, wireless or a combination of the two. The system can be fully validated and is compliant with all appropriate quality and regulatory standards: GMP, GLP, GxP, FDA 21 CFR part 11, CAP, CAPA, HACCP, JCAHO, USP 797, etc. Our subscription-based pricing includes all hardware, any necessary maintenance, repairs, and support. In addition, our Safety Net group ensures that any alerts are quickly addressed, 24/7, 365 days a year. XiltriX protects your science and helps you sleep at night.